Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06194461 | LTFU for All Cell and Gene Therapy Studies(LOCUS) | not yet recruiting | — | 64 | AstraZenecaINDUSTRY | 4 | Jun 27, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 |
| NCT06643208 | D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC | recruiting | — | 37 | Fujian Provincial HospitalOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07038863 | Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France(Mondelta) | not yet recruiting | N/A | 2,000 | Hospices Civils de LyonOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07018518 | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT04348838 | Prospective Cohort of Patients With Hepatocellular Carcinoma in France(CHIEF) | recruiting | — | 5,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010198 | Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City | recruiting | — | 4,500 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk(SHORT) | not yet recruiting | N/A | 1,389 | Peking University People's HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06999707 | Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Photon-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06312826 | Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk | active not recruiting | N/A | 806 | Asan Medical CenterOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06995105 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04791735 | Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma(LapCHC) | active not recruiting | N/A | 252 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT04941287 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | May 23, 2025 | clinicaltrials |
| NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma(HAICI) | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT05660213 | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | not yet recruiting | — | 750 | Fudan UniversityOTHER | 0 | May 20, 2025 | clinicaltrials |
| NCT06978933 | FGF19 Overexpression Combination Unified Study in HCC-19(FOCUS-19) | recruiting | Phase 2 | 42 | RenJi HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05657249 | Alternative Surveillance Program for Patients With High Risk Group of HCC | active not recruiting | N/A | 199 | Seoul National University HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05763277 | Ate-Bev Early Response Prediction Model in Advanced HCC | recruiting | — | 170 | Seoul National University HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06280105 | A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib | recruiting | Phase 2 | 40 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06406816 | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection | recruiting | Early Phase 1 | 10 | Yongyi ZengOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06339424 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma(PhotonAB) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06379256 | Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy | recruiting | — | 300 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06383520 | Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma | recruiting | Early Phase 1 | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 24 | Yoon Jun KimOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971237 | SIRT and Peri-immunotherapy : a New Concept(IMSIRT) | not yet recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05409482 | A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma | recruiting | — | 300 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06966986 | Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma | active not recruiting | — | 130 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 / Phase 3 | 294 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06961526 | Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab | recruiting | N/A | 110 | Tanta UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06961617 | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06960863 | Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma | recruiting | — | 80 | Tanta UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06420440 | Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | recruiting | Phase 2 | 160 | Chen XiaopingOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06950827 | Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma | recruiting | — | 400 | West China HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06904196 | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC | recruiting | Phase 2 | 78 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06418659 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients | recruiting | Early Phase 1 | 37 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06583993 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients | recruiting | Early Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06940102 | Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors | recruiting | — | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06938451 | Relationship Between FGF19 Overexpression and Disease Prognosis(FGF19) | not yet recruiting | — | 100 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05128123 | Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF(SOCIAL-CHIEF) | active not recruiting | — | 1,600 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06934070 | Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection | active not recruiting | — | 287 | Qiang XuOTHER | 1 | Apr 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2025source: clinicaltrials